Showing results (11-20 of 18) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
American Journal of Nephrology|March 31, 2026
Effect of finerenone treatment discontinuation on kidney and cardiovascular outcomes: a FIDELITY analysisAjay K Singh, Stefan D Anker, Bertram Pitt, et al.Journal of Diabetes and Its Complications|November 25, 2025
Efficacy and safety of finerenone in Asian patients with type 2 diabetes and chronic kidney disease: A FIDELITY analysis by baseline kidney functionShigehiro Katayama, Stefan D Anker, Dalong Zhu, et al.Kidney International|November 11, 2022
A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetesGeorge L Bakris, Luis M Ruilope, Stefan D Anker, et al.Ophthalmology. Retina|July 7, 2019
Impact of Baseline Retinal Nonperfusion and Macular Retinal Capillary Nonperfusion on Outcomes in the COPERNICUS and GALILEO StudiesNicolas Feltgen, Yuichiro Ogura, Francesco Boscia, et al.Clinical Ophthalmology (Auckland, N.Z.)|September 9, 2017
Integrated results from the COPERNICUS and GALILEO studiesAmelie Pielen, W Lloyd Clark, David S Boyer, et al.Diabetes, Obesity & Metabolism|July 4, 2023
The impact of obesity on cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes treated with finerenone: Post hoc analysis of the FIDELITY studyPeter Rossing, Stefan D Anker, Gerasimos Filippatos, et al.Clinical Journal of the American Society of Nephrology : CJASN|March 17, 2023
Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup AnalysisPantelis Sarafidis, Rajiv Agarwal, Bertram Pitt, et al.Lancet (London, England)|June 5, 2026
Efficacy and safety of finerenone in patients with chronic kidney disease: an individual participant data pooled analysis (INFINITY)Brendon L Neuen, Hiddo J L Heerspink, Vlado Perkovic, et al.Pageof 2